Trastuzumab

Drug Profile

Trastuzumab

Alternative Names: Anti-c-erbB-2 monoclonal antibody; Anti-erbB-2- monoclonal antibody; Anti-HER-2 monoclonal antibody; Anti-p185HER-2 monoclonal antibody; HER-2; HER-2 human monoclonal antibody; HER-2 MAb; HER-2 monoclonal antibody; HER-2 murine monoclonal antibody; HER-2/neu MAb; HER-2/neu monoclonal antibody; Herceptin; Monoclonal antibody 4D5; R 597; RG597

Latest Information Update: 08 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Genentech; Memorial Sloan-Kettering Cancer Center
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Northwestern University; Roche; Sanofi; West German Study Group
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer
  • Phase II Colorectal cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Urogenital cancer

Most Recent Events

  • 01 Jun 2017 Interim adverse events and efficacy data from the phase II PATRICIA trial in Breast cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 13 Mar 2017 Mylan withdraws its Inter Partes Review (IPR) challenges against two US Genentech patents (No. 6 407 213 and 6 331 415)
  • 24 Jan 2017 Roche completes a phase II trial for Gastric cancer (combination therapy) in Germany (NCT01472029)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top